Annalisa Berzigotti
Overview
Explore the profile of Annalisa Berzigotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
254
Citations
5826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kolev M, Moller B, Berzigotti A, Semmo N
J Hepatol
. 2025 Mar;
PMID: 40086476
No abstract available.
2.
Ardoino M, Zbinden L, Klaus J, Peters A, Catucci D, Bronnimann M, et al.
Rofo
. 2025 Mar;
PMID: 40064326
To determine whether the nonfunctional liver volume (NFLV) is an indicator of chronic liver disease (CLD).Multiparametric 3T abdominal MRI examinations enhanced with gadobenate dimeglumine of 51 patients were included in...
3.
4.
Mandorfer M, Abraldes J, Berzigotti A
JHEP Rep
. 2025 Mar;
7(3):101300.
PMID: 40034396
Portal hypertension (PH) leads to life-threatening clinical manifestations such as bleeding from gastro-oesophageal varices, ascites and its complications, and portosystemic encephalopathy. It can develop because of advanced chronic liver disease...
5.
van Beurden W, Mendoza Y, Lange N, Bosch J, Berzigotti A, Rodrigues S
J Diabetes Complications
. 2025 Feb;
39(3):108978.
PMID: 39999536
Background & Aims: Patients with compensated advanced chronic liver disease (cACLD) and treated type 2 diabetes have an increased risk for liver-related events, but data regarding this population is lacking,...
6.
Vana M, Fidan K, Berzigotti A, Lange N
Praxis (Bern 1994)
. 2025 Feb;
114(1):18-22.
PMID: 39964381
Due to widespread diseases with increasing numbers of patients, such as metabolic syndrome, metabolic liver diseases are becoming the most common liver diseases of the future. The article explains key...
7.
Newsome P, Tacke F, Wedemeyer H, Rimassa L, Berzigotti A, Karlsen T, et al.
J Hepatol
. 2025 Feb;
82(3):399-402.
PMID: 39956767
No abstract available.
8.
Strajhar P, Berzigotti A, Nilius H, Nagler M, Dufour J
PLoS One
. 2025 Jan;
20(1):e0317629.
PMID: 39854322
Background & Aims: Chronic liver diseases pose a serious public health issue. Identifying patients at risk for advanced liver fibrosis is crucial for early intervention. The Fibrosis-4 score (FIB-4), a...
9.
Newsome P, Tacke F, Wedemeyer H, Rimassa L, Berzigotti A, Karlsen T, et al.
J Hepatol
. 2025 Jan;
82(1):1-3.
PMID: 39836510
No abstract available.
10.
Lyshchik A, Kuon Yeng Escalante C, Siu Xiao T, Piscaglia F, Kono Y, Medellin-Kowalewski A, et al.
Radiology
. 2025 Jan;
314(1):e240916.
PMID: 39835975
Background Indeterminate focal liver observations in patients at risk for hepatocellular carcinoma (HCC) may require invasive biopsy or follow-up, which could lead to delays in definitive categorization and to postponement...